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Graphical Abstract
Predicted incidence of an aneurysm-related event at 1 year (A) and 3 years (B) after recruitment by aneurysm size and age. One-year risk remains below
10% for aneurysms up to 7 cm for patients aged 60, 70, and 80 years.
...................................................................................................................................................................................................
* Corresponding author. Tel: þ44 2076127862, Email: Linda.Sharples@lshtm.ac.uk
VC The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal (2021) 00, 1–14 CLINICAL RESEARCH




/eurheartj/advance-article/doi/10.1093/eurheartj/ehab784/6446067 by London School of H
ygiene & Tropical M




















































Prospective study of UK National Health Service (NHS) patients aged >_18 years, with new/existing arch or
descending thoracic aortic aneurysms of >_4 cm diameter, followed up until death, intervention, withdrawal, or July
2019. Outcomes were aneurysm growth, survival, quality of life (using the EQ-5D-5L utility index), and hospital
admissions. Between 2014 and 2018, 886 patients were recruited from 30 NHS vascular/cardiothoracic units.
Maximum aneurysm diameter was in the descending aorta in 725 (82%) patients, growing at 0.2 cm (0.17–0.24) per
year. Aneurysms of >_4 cm in the arch increased by 0.07 cm (0.02–0.12) per year. Baseline diameter was related to
age and comorbidities, and no clinical correlates of growth were found. During follow-up, 129 patients died, 64
from aneurysm-related events. Adjusting for age, sex, and New York Heart Association dyspnoea index, risk of
death increased with aneurysm size at baseline [hazard ratio (HR): 1.88 (95% confidence interval: 1.64–2.16) per
cm, P < 0.001] and with growth [HR: 2.02 (1.70–2.41) per cm, P < 0.001]. Hospital admissions increased with aneur-
ysm size [relative risk: 1.21 (1.05–1.38) per cm, P = 0.008]. Quality of life decreased annually for each 10-year in-
crease in age [–0.013 (–0.019 to –0.007), P < 0.001] and for current smoking [–0.043 (–0.064 to –0.023), P = 0.004].
Aneurysm size was not associated with change in quality of life.
...................................................................................................................................................................................................
Conclusion International guidelines should consider increasing monitoring intervals to 12 months for small aneurysms and
increasing intervention thresholds. Individualized decisions about surveillance/intervention should consider age, sex,
size, growth, patient characteristics, and surgical risk.
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Introduction
Chronic thoracic aortic aneurysm (CTAA) of the arch or descending
thoracic aorta (DTA) is life-threatening if undiagnosed or neglected
as aneurysms expand. Aneurysm growth is associated with dissection
(tearing) or rupture of the aortic wall. In general, after diagnosis, 6-
month mortality in treated and untreated patients with CTAA is esti-
mated to be 17.7% and 30%, respectively.1
The condition is rare, but recorded incidence is rising. UK hospital
admissions for thoracic aortic aneurysm increased from 4.4 to 9.0
per 100 000 inhabitants between 1999 and 2010.2 This was probably
secondary to greater availability of computed tomography (CT) scan-
ning, in an increasingly elderly population.
Treatment of CTAA confers a significant risk of mortality and mor-
bidity, significant post-operative recovery period, and cost.3 Small
aneurysms are monitored by CT or magnetic resonance imaging
(MRI), and repair offered if perceived risk of rupture/dissection signifi-
cantly increases. This follows rapid growth, worsening symptoms, or
the CTAA reaching a critical size. In the infra-renal aorta, randomized
controlled trials have demonstrated that surveillance is safe up to
5.5 cm4 and these principles have informed current guidelines.5 This
is not the case for CTAA. Although guidelines have been formulated,
evidence for the most effective surveillance and intervention strat-
egies is sparse.6,7 Previous registries have been limited by lack of pro-
spective follow-up data.8 As a result, there is substantial variation in
practice. Evidence that informs robust surveillance strategies should
highlight those at risk of aneurysm-related death and should inform
optimal timing of repair for individuals. This information is needed
urgently.
Using data from the Effective Treatments for Thoracic Aortic
Aneurysms (ETTAA) study, the overall aim of this article is to de-
scribe the natural history of CTAA prior to intervention, docu-
ment risks, and health-related quality of life (HRQoL) during
surveillance and identify those at high-risk of aneurysm-related
death. Specific objectives are: (i) to model growth over time, prior
to any major intervention; (ii) to describe survival patterns and
their relationship to changing aneurysm diameter and HRQoL in
the absence of major interventions; (iii) to describe major
aneurysm-related events of rupture and dissection; (iv) to model
HRQoL over time, prior to any major intervention; and (v) to




ETTAA is an observational cohort study of current clinical practice at the
time of the study. The protocol is published and a funder’s report will be
released in 2022.9,10 Patients aged >_18 years, attending National Health
Service (NHS) hospitals in England between March 2014 and July 2018,
with previously or newly diagnosed aneurysms of >_4 cm diameter in the
arch or DTA (extending to thoraco-abdominal aorta) were eligible for
ETTAA. These included aneurysms associated with atherosclerosis, acute
dissection in adjacent segments, and aortopathy. Isolated ascending aortic
aneurysms were not included. However, patients with ascending aortic
aneurysm adjacent to arch aneurysms (over 4 cm) were included. Study
centres provided a copy of the chest CT or MRI radiological scan nearest
to recruitment and the accompanying report needed to confirm an
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eligible aneurysm. Exclusion criteria were acute dissection with or with-
out malperfusion syndromes and previous surgical intervention for an an-
eurysm in the same segment.
At consent treating clinicians grouped patients according to intended
management: conservative management (CM) if aneurysms were at risk of
rupture, but surgical and endovascular procedures were not planned due
to patient choice, comorbidities, or procedural risk; watchful waiting
(WW) if aneurysms were small, at low risk of rupture, and surgical and
endovascular procedures were not recommended but were options for
future management; endovascular stent grafting (ESG); and open surgical re-
placement (OSR).
This paper reports on data from all patients in ETTAA before interven-
tion. Patients assigned to WW, ESG, and OSR were collectively
described as intention to treat (ITT). Changes in intended management
during the study were recorded but there was no attempt to intervene in
this observational study.
Data collection
Data were collected prospectively by local research staff, co-ordinated
by Papworth Trials Unit Collaboration. Patient characteristics, maximum
aneurysm diameter, clinical events, hospital admissions, cardiac or vascu-
lar surgery, and HRQoL were recorded at consent, 3, 6, 12, 18, 24, 36,
and 48 months, until the end of the follow-up period on 31 July 2019.
Retrospective CT and MRI data were collected from sites for the
measurement of aneurysm growth.
Patients contributed data from either date of diagnosis (aneurysm
growth) or date of recruitment (HRQoL, survival, clinical events) until
first intervention, death, major clinical event, withdrawal, or end of the
study, whichever occurred first.
Outcomes
The four outcomes of interest were overall survival (primary), aneurysm-
related survival, and longitudinal trajectories for aneurysm growth and
HRQoL.
Survival time was calculated from centre-reported data, as date of con-
sent to date of death. Surviving patients were censored at withdrawal,
date of surgical treatment (ESG or OSR) for the aneurysm, or end of the
study, whichever was first. For aneurysm-related survival, deaths from
other causes were treated as censored.
Maximum aneurysm diameter was measured by CT or MRI during
routine care, using local protocols. Anonymized CT/MRI scans were re-
analysed at St George’s Hospital (London, UK) or Papworth Hospital
(Cambridge, UK) core labs to minimize observer differences. Five opera-
tors analysed CT scans [two at St Georges (n = 269 scans) and three at
Papworth (n = 1268 scans)]. Centres agreed a standard protocol and
used the same 3Mensio software, recording diameters from two-
dimensional images (see Supplementary material online). MRI scans were
analysed at Papworth by two radiology consultants (n = 125). If scans
were not returned to core labs by the date of analysis, we took scan
measurements provided by the participating hospital (n = 70). All avail-
able aneurysm measurements from recruited patients were included in
the analysis, including those taken prior to recruitment. The maximum
diameter observed was analysed, classified as upper thoracic aorta if the
maximum diameter was located in the ascending aorta (n = 93, 10.5%) or
arch (n = 59, 6.7%), and lower if it was in the DTA (n = 725, 81.8%) or
thoraco-abdominal aorta (n = 9, 0.1%). Note that all aneurysms had a
diameter of >_4 cm in arch or DTA, although the maximum diameter may
have been in an adjacent segment.
Aneurysm-related clinical events requiring hospital admission were
collected by the local hospital. All events were reviewed centrally by
ETTAA clinicians (P.S. and S.L.).
HRQoL was assessed by the EQ-5D-5L questionnaire at the local hos-
pital.11 Based on recommendations from the UK National Institute for
Health and Care Excellence, responses were converted into EQ-5D-3L
index values (value assigned to reported health state) using the crosswalk
approach.12 The index ranges from one (maximum health), through zero
(equivalent to death), to –0.59; values < 0 indicate health states consid-
ered worse than death. This provides a simple, one-dimensional generic
measure of HRQoL with an intuitive measurement scale.
Statistical methods
Full details of statistical methods are reported elsewhere.10
Sample size
Sample size calculations for ETTAA were based on comparing survival
between patients who underwent ESG and OSR during the study, and
are not relevant to the pre-intervention analysis here.
Exploratory analysis
Baseline measurements and missing data were summarized; ITT and CM
groups were compared using Student’s t-tests and Pearson’s v2 test as ap-
propriate. Time to event data were summarized using Kaplan–Meier esti-
mates and compared using log-rank tests. Frequency and simple event
rates per patient-year were summarized for deaths and hospital admis-
sions, with ruptures, dissections, and neurological events reported
separately.
Survival, hospital admissions, rupture, dissection, and
neurological events
Cox proportional hazards models were developed to assess relationships
between survival and baseline variables. Schoenfeld residual plots and
tests verified proportional hazards assumptions. Centre effects were
assessed using gamma frailty terms but were not significant and are not
reported. The above analysis censors patients who have ESG and OSR
on the date of the procedure; that is, we assume they have the same risk
of death as people with similar aneurysms who remain in the ITT group.
Because this assumption is unlikely to be true, we estimated risk factors
for the composite outcome of death or intervention in a sensitivity ana-
lysis. Negative binomial regression was used to compare hospital admis-
sion rates, adjusted for age and sex.
Longitudinal data
For maximum aneurysm size, time zero was defined by the first recorded
scan. HRQoL was analysed from the date of recruitment to ETTAA.
Exploratory analysis involved plotting distributions and trajectories over
time. Longitudinal measurements of aneurysm diameter and HRQoL
were analysed using linear random effects models. Variables considered
as fixed effects included time, sex, age, height, weight, body mass index,
smoking (current, ex-smoker, never), hypertension, chronic obstructive
pulmonary disease (COPD), connective tissue disorders, coronary artery
disease, extra-cardiac arteriopathy, heart valve disease, type of scan (CT,
MRI), and aneurysm location (arch/ascending, DTA/thoraco-abdominal
aorta). Non-linear changes over time were assessed by including time-
squared in the model, but were not significant. All continuous variables
except time of assessment were centred at the mean. A linear term was
included for New York Heart Association (NYHA) class. Patient and
centre random effects (intercept and slope over time) were investigated,
but only patient effects were significant in any analysis. For patients who
were recruited with >_4 cm arch aneurysms, models for growth in the
ascending thoracic aorta and the arch diameter were also fitted
separately.
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Joint analysis of longitudinal measurements and survival
To investigate whether aneurysm diameter and HRQoL changes over
time were related to overall or aneurysm-related deaths, we fitted joint
random effects models for growth/HRQoL and time to death.13 Based
on analysis of longitudinal trajectories alone, linear models with normally-
distributed residuals were assumed. Significant predictors identified in
longitudinal and survival models were included in the joint model. Models
were fitted using the stjm commands in Stata v16.14
Missing data
Mandated variables for ETTAA had few missing values (<8%) (Appendix
1). Variables with >25% missing data were not used in modelling.
Complete case analysis was used for longitudinal data measurements
since estimates from such models are unbiased provided that the data are
missing at random (MAR) conditional on the observed data.15 For survival
models, sensitivity analysis assuming MAR used multiple imputation with
chained equations and predictive mean matching. Imputation models
included the outcome variable as well as all important covariates from ex-
ploratory analysis. Resulting models were combined using Rubin’s rules.16
Results
ETTAA patient cohort
Between March 2014 and July 2018, 886 patients were recruited
from 30 UK centres. At recruitment, 82 (9.3%) were assigned CM, ei-
ther at patient request or clinician judgement. Six later underwent
ESG or OSR, leaving 76 ‘true’ CM patients at baseline. During follow-
up, 36 additional patients were transferred to CM due to deterior-
ation, comorbidities, or patient preference. Thus, 112 patients
(12.6%) were ultimately assigned to CM. The remaining 774 (91.6%)
patients were classified as ITT.
Median time between consent and leaving follow-up/end of study
was 20.3 (0–61) months. Reasons for leaving follow-up were ESG/
OSR (n = 285), death (n = 129), and withdrawal (n = 30); the remain-
ing 442 patients were censored at the end of follow-up.
Baseline measurements
The ETTAA cohort included 321 (36.2%) women and 565 men, with
mean [standard deviation (SD)] age of 70.9 (10.9) years.
Comorbidities are listed in Table 1.
Survival
Eighty-three ITT patients (6.6% deaths per patient-year) and 46 CM
patients (20.0% per patient-year) died during follow-up, for a total of
129 patients (8.6% per patient-year). Sixty-four (49.4%) deaths were
aneurysm-related (45 ruptures, 11 dissections, 3 ruptured and dis-
sected, and 5 aneurysm-related but specific event not reported).
Thirty-nine aneurysm-related deaths were in ITT patients (3.0% per
patient-year) and 25 in CM patients (11% per patient-year). Of 307
patients with aneurysms >_6 cm, 76 died (23.1% per patient-year), of
which 42 were aneurysm-related deaths (12.7% per patient-year).
One and 3-year survival rates were 92.4% (90.2–94.1) and 77.6%
(73.4–81.2), respectively. Analogous figures for aneurysm-related
death were 96.5% (94.8–97.6) and 88.3% (84.8–91.0), respectively.
Nineteen ITT patients were recruited on the day of surgery and
were excluded from this analysis.
In unadjusted analysis, ITT patients had significantly lower overall
and aneurysm-related death rates compared with CM patients [haz-
ard ratio (HR): 0.35 (95% confidence interval: 0.23–0.47) and 0.28
(0.17–0.47), respectively, P < 0.001 for both]. Patients with larger
aneurysms at baseline, women, older age, formal/informal care, previ-
ous cardiac interventions, COPD, higher NYHA class, and those with
smaller height and weight had significantly higher risk of death
(Appendix 2).
In multivariable analysis, apart from age, sex, and (possibly) NYHA
class, only maximum aneurysm size at baseline was a strong risk fac-
tor for overall and aneurysm-related death, approximately doubling
risk for each centimetre increase in maximum diameter (Table 2). ITT
and comorbidity markers were not significant once age, sex, aneur-
ysm size, and NYHA were included. Figure 1 shows predicted overall
and aneurysm-related mortality rates by maximum aneurysm diam-
eter at baseline, for people who had average values of age, sex, and
NYHA class. Given average covariates, patients with aneurysms of
maximum diameter 4–6 cm had predicted 1-year mortality below
10%, which increases to 12.4% and 22.2% for 7 cm and 8 cm aneur-
ysms, respectively. By 3 years, patients with 6 cm aneurysms have
predicted mortality of 21.3%, whilst probabilities for those with 7 cm
and 8 cm aneurysms have increased to 36.5% and 57.7%, respectively.
If we consider only deaths described as aneurysm-related, mortality
rates were lower, with only large (>8 cm) aneurysms rising above
10% at 1 year and 40% at 3 years.
The Graphical Abstract shows additional effect of age on incidence
of aneurysm-related death or non-fatal dissection/rupture at 1 and
3 years; incidence remains below 10% for aneurysms up to 7 cm even
for 80-year olds, but increases rapidly in this age group between 1
and 3 years.
Multiple imputation for missing covariates gave almost identical
results (Appendix 1).
Repeating the analysis for the composite outcome of death or
intervention, the HRs for overall and aneurysm-related death for
each 1 cm increase in maximum aneurysm diameter were 1.72 (1.59–
1.86) and 1.81 (1.66–1.98), respectively (both P < 0.001).
Aneurysm diameters at baseline and
growth over time
The largest aneurysm was in the DTA for 636 (82.2%) ITT patients
and 89 (79.5%) CM patients. Mean (SD) maximum diameter at base-
line was 5.6 cm (1.1) in ITT patients and 6.3 cm (1.2) in CM patients.
After excluding scans using techniques other than CT or MRI (n = 11)
and one scan dated 20 years before ETTAA, 1767 scans in 882
(99.5%) patients were included. Times between first and subsequent
scans ranged from 3 days to 7.35 years.
The final model describing diameter measurement trajectories in
the absence of treatment is shown in Appendix 3. Average (max-
imum) diameter in the DTA at baseline for a person of average age,
with no comorbidities was 5.57 cm (5.48–5.67). At first scan, larger
aneurysms were found for older patients [mean difference per 10-
year increase in age = 0.18 cm (0.11–0.5), P < 0.001], connective tis-
sue disorders [0.39 cm larger (0.06–0.72), P = 0.019], and COPD
[0.21 cm larger (0.02–0.40), P = 0.032]. At baseline, adjusting for age,
scan type, and comorbidities, the mean difference between maximum
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Table 1 Patient characteristics at recruitment according to intention to treat
Variables Patient subgroup
or summary
ITT (n 5 774) CM (n 5 112) Mean difference or odds ratio
(95% CI) and P-values*
Age (years) Mean (SD) 70.0 (10.7) 76.6 (9.9) 6.6 (4.5, 8.7)
(min–max) (31.6–92.5) (26.1–92.5) P < 0.001
Sex Female, n (%) 273 (35.3) 48 (42.9) 0.73 (0.49–1.09)
Male, n (%) 501 (64.7) 64 (57.1) P = 0.120
Height (cm) Mean (SD) 171.4 (10.5) 167.4 (12.5) –4.03 (–6.24 to –1.81)
(min–max) (138–210) (132–216) P < 0.001
Missing, n (%) 26 (3.4) 9 (8.0)
Care Formal/informal, n (%) 80 (10.3) 23 (20.6) 0.44 (0.27–0.74)
None, n (%) 688 (88.9) 88 (78.6) P = 0.002
Missing, n (%) 6 (0.8) 1 (0.9)
Smoking Current, n (%) 99 (12.8) 14 (12.5) 1.27 (0.66–2.44)
Past, n (%) 446 (57.6) 57 (50.9) 1.40 (0.91–2.17)
Never, n (%) 223 (28.8) 40 (35.7) –
Missing, n (%) 6 (0.8) 1 (0.9) P = 0.307
Connective tissue disorder Yes, n (%) 52 (6.7) 3 (2.7) 2.62 (0.80–8.53)
No, n (%) 722 (93.3) 109 (97.3) P = 0.098
Coronary artery disease CABG, n (%) 41 (3.3) 10 (8.9) 0.57 (0.27–1.17)
PCI, n (%) 34 (4.4) 6 (5.4) 0.78 (0.32–1.92)
Medication, n (%) 68 (8.8) 9 (8.0) 1.04 (0.50–2.17)
No, n (%) 15 (1.9) 2 (1.8) Reference
Missing, n (%) 616 (79.6) 85 (75.9) P = 0.443
Extracardiac arteriopathy Yes, n (%) 113 (14.6) 20 (17.9) 1.26 (0.75–2.12)
No, n (%) 647 (83.6) 91 (81.3) P = 0.389
Missing, n (%) 14 (1.8) 1 (0.9)
Heart valve disease Yes, n (%) 142 (18.3) 23 (20.5) 0.87 (0.53–1.42)
No, n (%) 619 (80.0) 87 (77.7) P = 0.574
Missing, n (%) 13 (1.7) 2 (1.8)
Left ventricular function (not mandated) Good, n (%) 342 (44.2) 41 (36.6) Reference
Moderate, n (%) 62 (8.0) 14 (12.5) 0.53 (0.27–1.03)
Poor, n (%) 13 (1.7) 2 (1.8) 0.78 (0.17–3.57)
Not measured, n (%) 347 (44.8) 55 (49.1) P = 0.267
Missing, n (%) 10 (1.3) 0 (0.0)
Diabetesa Yes, n (%) 76 (9.8) 7 (6.3) 1.64 (0.74–3.65)
No, n (%) 695 (89.8) 105 (93.8) P = 0.222
Missing, n (%) 3 (0.4) 0 (0.0)
Documented hypertension Yes, n (%) 678 (87.6) 97 (86.6) 1.12 (0.62–2.00)
No, n (%) 94 (12.1) 15 (13.4) P = 0.714
Missing, n (%) 2 (0.3) 0 (0)
Chronic obstructive pulmonary disease Yes, n (%) 137 (17.7) 26 (23.2) 0.72 (0.45–1.15)
No, n (%) 632 (81.7) 86 (76.8) P = 0.169
Missing, n (%) 5 (0.6) 0 (0.0)
NYHA class I, n (%) 320 (41.3) 39 (34.8) Reference
II, n (%) 274 (35.4) 41 (36.6) 0.81 (0.51–1.30)
III, n (%) 123 (15.9) 27 (24.1) 0.56 (0.33–0.95)
IV, n (%) 23 (3.0) 3 (2.7) 0.93 (0.27–3.26)
Missing, n (%) 34 (4.4) 2 (1.8) P = 0.185
Any anti-hypertensive medication Yes, n (%) 659 (85.1) 94 (83.9) 1.10 (0.64–1.89)
No, n (%) 115 (14.9) 18 (16.1) P = 0.737
Statins Yes, n (%) 440 (56.8) 72 (64.3) 0.74 (0.49–1.11)
No, n (%) 332 (42.9) 40 (35.7) P = 0.144
Missing, n (%) 2 (0.3) 0 (0.0)
CI, confidence interval; CM, conservative management; IDDM, insulin-dependent diabetes mellitus; ITT, intention to treat.
aThree cases of IDDM in ITT groups, all others non-IDDM.
*P-value from hypothesis test of zero mean difference or odds-ratio = 1.
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..diameter in upper and lower sections of the thoracic aorta was small
[–0.10 cm (–0.30 to 0.09), P = 0.296].
Maximal aneurysms in the DTA grew by 0.20 cm per year (0.17–
0.24) (P < 0.001); those in the upper thoracic aorta did not grow on
average [–0.007 cm (–0.08 to 0.07), P = 0.850]. Figure 2 summarizes
average growth trajectories in each section. In additional analysis, an-
nual growth rate in the large (>_4 cm) arch aneurysms alone was
0.068 cm (0.017–0.118) (P = 0.009), whilst aneurysm diameter in the
ascending thoracic aorta did not increase [–0.070 cm (–0.149 to
0.010), P = 0.085]. There was no evidence that aneurysm growth
accelerated or decelerated during follow-up. After adjusting for base-
line variables, there was significant between-patient variation in max-
imum aneurysm size (random effects SD: 1.06 cm). Additionally,
there was significant unexplained (by available covariates) between-
patient variation in growth rate (random effects SD: 0.17 cm/year).
Adjusting for covariates, patients with larger maximal diameters at
baseline also had faster growth (correlation: 0.40). At first scan, there
was no difference between aneurysm diameters measured by CT
and MRI, all other variables being equal. However, the average differ-
ence between diameters measured by the two modalities increased
over time by 0.14 cm per year (0.08–0.21) (P < 0.001), with MRI
measurements being smaller (Appendix 3).
Joint analysis of growth and survival
Adjusting for location of the aneurysm with maximal diameter and
intended management, current (rather than baseline) diameter was
significantly associated with overall survival (Appendix 4). Each 1 cm
increase in the maximal diameter within a patient more than doubled
the risk of overall death [HR: 2.02 (1.70–2.41)] and aneurysm-related
death [HR: 2.35 (1.85–2.99)] for that individual (both P < 0.001).
Baseline diameter and current diameter were correlated, and models
including both suggested that current aneurysm size is a more im-
portant risk factor than size when presenting at multi-disciplinary
team meetings.
Hospital admissions
Centres reported 363 hospital admissions in 222 patients during
follow-up (Table 3). Admission rates were related to maximum an-
eurysm diameter, increasing by 21% per cm increase in size at base-
line [relative rate 1.21 (1.05–1.38), P = 0.008]. ITT patients were less
likely to be readmitted than CM patients [odds ratio: 0.53 (0.35–
0.80)], although admission rates per person were not significantly
higher. Fifty-two (definitely/probably) aneurysm-related hospital
admissions were recorded for 39 patients. Although aneurysm-
related admissions increased by aneurysm size [relative rate: 1.48 per
cm (0.93–2.26), P = 0.10], this was not statistically significant (at 5%).
Nine non-fatal aneurysm-related events were reported (two rup-
tures, seven dissections): three had CT scans in the previous month,
maximum aneurysm diameters were 5.64 cm, 6.91 cm, and 8.29 cm;
the six with no scans within the previous 6 months, maximum diame-
ters ranged from 4.56 cm to 6.98 cm. Eight non-fatal neurological
events were reported.
HRQoL pre-intervention
During ETTAA, 3732 HRQoL questionnaires were returned by 886
patients. After excluding blank forms (n = 256), duplicate entries
(n = 11), and incomplete forms (n = 35), 3492 (93.6%) remained.
Overall 855 of 886 (96.5%) patients completed between one and
nine EQ-5D-5L questionnaires. Mean (SD) utilities at baseline for ITT
and CM patients were 0.73 (0.24) and 0.68 (0.25), respectively.
The final model describing HRQoL trajectories in the absence of
ESG or OSR is shown in Appendix 5. At recruitment (time zero),
mean HRQoL was 0.84 (0.81–0.86) for a person of average age
(70.9 years), in NYHA class I, who has never smoked, and did not
have formal/informal care. Baseline HRQoL decreased as NYHA
class increased [I—0.84 (0.81–0.86); II—0.74 (0.71–0.76); III—0.63
(0.60–0.67); IV—0.53 (0.49–0.58), P < 0.001] (all else equal).
Reported requirement for formal/informal care was associated with
large deficit in HRQoL at recruitment [mean = 0.66 (0.61–0.70),
P < 0.001]. Average age at recruitment was 70.9 years, and HRQoL at
recruitment was slightly larger for older patients by 0.010 (–0.003 to
0.022) (P = 0.122) per decade, possibly due to selection policies.
Current smokers had worse HRQoL at recruitment of 0.79 (0.75–
0.83) compared with ex-smokers [0.84 (0.82–0.86)] and never smok-
ers [0.84 (0.81–0.86), P = 0.057].
For relatively fit, non-smoking patients, of average age, mean
HRQoL did not change significantly over time, estimated decrease
was –0.010 (–0.022 to 0.003) (P = 0.132 per year). However, the
interaction between follow-up time and age showed that if two
patients differed in age by 10 years, the older patient would have a
faster decrease in HRQoL of –0.013 (–0.019 to –0.007; P < 0.001 per
year) (all else being equal). As a result, the difference between age
groups increased over time thereafter. Current smokers had a faster
decline in HRQoL over time [–0.043 (–0.064 to –0.023), P = 0.004
per year]. Figure 3 shows that, for this cohort, current smoking had a
much greater influence on HRQoL than a 10-year increase in age.
Significant random effects indicated that HRQoL varied between
patients both at recruitment and in the rate of decline over time, in
..................................................... ............................................................
....................................................................................................................................................................................................................
Table 2 Multivariable Cox regression results for all-cause and aneurysm-related deaths, complete case analysis
All-cause deaths Aneurysm-related deaths
Variable HR (95% CI) P-value HR (95% CI) P-value
Female sex 1.78 (1.24–2.54) 0.002 2.60 (1.58–4.29) <0.001
Age at consent (per decade) 1.80 (1.42–2.27) <0.001 1.50 (1.09–2.05) 0.012
Baseline NYHA per class 1.23 (1.00–1.52) 0.054
Baseline maximum aneurysm size per cm 1.88 (1.64–2.16) <0.001 2.16 (1.79–2.61) <0.001
CI, confidence interval; HR, hazard ratio; NYHA, New York Heart Association.
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addition to the variation that could be attributed to the variables in
the model.
Joint analysis of changes in HRQoL and
survival
After adjusting for age, sex, aneurysm size, and NYHA class, there
was weak evidence that current HRQoL was associated with overall
death [HR per 0.1 unit decrease in HRQoL: 0.90 (0.82–0.99),
P = 0.032], but not aneurysm-related death [HR: 1.00 (0.86–1.16),
P = 0.963] (Appendix 6).
Discussion
Summary of findings
This paper reported aneurysm growth, hospital admissions, survival,
and HRQoL in a large group of patients.
Aneurysms with maximum diameter in the DTA grew significantly
faster, and (adjusting for comorbidity and aneurysm location) patients
with larger aneurysms at baseline had faster growth (Appendix 3, cor-
relation 0.4). No clinical risk factors for accelerated growth were
identified, despite significant between-patient variation. This may re-
sult from short and infrequent follow-up, the relatively stable nature
of most patients and selection of high-risk patients for ESG or OSR.
The cohort required frequent hospital admissions and there was
high risk of death before intervention even in those undergoing sur-
veillance with a view to treatment (8.6% per year overall and 6.6%
per year in the ITT group). There were few non-fatal dissections and
ruptures. After adjusting for age, sex, and NYHA class, aneurysm size
at baseline and growth were the most significant variables affecting
overall and aneurysm-related survival. A 1 cm increase in size, either
between patients at baseline, or growth within a patient, doubled the
hazard of death. Admissions to hospital also increased with aneurysm
size. HRQoL (measured by EQ-5D-5L) was not related to aneurysm
size, and remained high in ‘healthy’ patients. Baseline HRQoL was
related to need for supportive care, NYHA class, and smoking
Figure 1 Predicted proportion dying from any cause (A) and aneurysm-related causes (B) using fitted Cox regression models by maximum aneur-
ysm diameter at baseline, with age, sex, and New York Heart Association class set to the average values.
Figure 2 Estimated mean (95% confidence interval) aneurysm
diameter over time by site of maximum measurement.
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activity. Decline in HRQoL over time was related to increasing age
and current smoking.
Relationship to external evidence and
interpretation of results
All-cause death rate in ETTAA was 8.6% per patient-year, with 3-
year survival of 77.6%. According to UK Government 2015–17 statis-
tics, the 1-year probability of death for English men and women aged
71 years, in the general population, was 2.1% and 1.4%, respectively,
with 3-year survival of 93.4% and 95.5%, respectively, substantially
higher than reported in this study.17 Only half the observed deaths
were aneurysm-related, suggesting that the ETTAA population also
had higher risk of death from causes not related to the aneurysm,
such as comorbidities with similar risk factors (e.g. smoking, hyper-
tension). These comorbidities also partly explain high rates of hos-
pital admission. Attention to treatment of significant comorbidity and
cardiovascular risk factor control to reduce the risk of major cardiac,
cerebral, and other arterial events is important in this group of
patients.
Survival outcomes
ETTAA results suggest that large aneurysms should be treated with
minimum delay since 3-year probability of death jumps from just
under 12% for ‘average’ patients with 5 cm aneurysms to over 35% if
the aneurysm increases to 7 cm (Figure 1). These increases will be
greater for women and older patients. Similarly, 3-year risk of
aneurysm-related death jumps from approximately 5% for aneurysms
of 5 cm to over 20% for aneurysms of 7 cm.
The increase in mortality with age was expected. The higher risk of
death for women in ETTAA is more difficult to explain. Women may
present at a later stage in their disease or when they also have other
life-threatening comorbidities, but this should not be assumed. It may
be that comorbidities in women are less well investigated or treated
or that aneurysm behaviours are different. There was no evidence
that women had longer follow-up after consent than men, so that any
delays were likely to occur prior to referral to participating multi-
disciplinary teams. Further investigation into causes of differences in
outcomes between sexes is warranted.
Comparisons of CM and ITT patients showed that clinicians suc-
cessfully identify high-risk patients based on demographic, clinical,
and aneurysm characteristics. However, transfer of patients between
management groups in a relatively short follow-up period and the
....................................................................................................................................................................................................................
Table 3 Clinical events and hospital admissions prior to any surgical or endovascular interventions
Patient subgroup ITT (n 5 774) CM (n 5 112) Simple comparisons (n 5 886)
Total time at risk (years) 1268.3 229.9
Median follow-up (years) 1.35 2.06 –
(minimum–maximum) (0–5.11) (0.003–4.54)
All admissions, n (rate/patient-year) Relative admission rate
292 (0.23) 71 (0.31) 0.77 (0.56–1.07)
P = 0.116
Admissions, definitely/probably aneurysm-related, n (rate/patient-year) Relative admission rate
41 (0.03) 11 (0.05) 0.59 (0.28–1.24)
P = 0.165
People with at least one admission, n (%) Odds ratio
181 (23.4) 41 (36.6) 0.53 (0.35–0.80)
P = 0.003
Patients admitted, definitely/probably aneurysm-related, n (%) Odds ratio
30 (3.9) 9 (8.0) 0.46 (0.21–1.00)
P = 0.050
Non-fatal ruptured aneurysms 2 0 –
Non-fatal dissected aneurysms 6 1 –
Non-fatal neurological events 7 1 –
CM, conservative management; ITT, intention to treat.
Figure 3 Average utility trajectories over time by age and smok-
ing habits.
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high death rate suggests remaining uncertainty about whether and
when to intervene. Better risk profiling methods are needed for these
aneurysms to guide clinicians.
Aneurysm size and growth
ETTAA raises questions regarding current guidance. Updated guide-
lines from the AHA/ACC suggest reimaging arch aneurysms to
detect enlargement at 12-month intervals if <4.0 cm diameter and 6-
month intervals for 4.0–5.4 cm diameter.18 In ETTAA, average
growth rates were 0.20 cm (0.17–0.24) per year in the DTA and
lower in the arch, so that yearly scanning may be more appropriate
for small aneurysms, even in the arch.
European and American Society guidelines for vascular and cardiac
surgery recommend consideration of ESG in patients with suitable
anatomy and maximal diameter >_5.5 cm and open surgery for
patients with unsuitable anatomy at 5.5–6.0 cm.6,7 For DTA/thoraco-
abdominal aneurysms, elective surgery is recommended if the aortic
diameter exceeds 6.0 cm, or if a connective tissue disorder is present.
The European Society for Vascular Surgery stated that ‘An initial
diameter of 60 mm carries an annual risk of rupture of 10%’.19 In
ETTAA, predicted 1-year aneurysm-related event probabilities for
average ETTAA patients with aortic aneurysms of 6 cm, 7 cm, and
8 cm were 3.5%, 7.1% and 13.8%, respectively. Furthermore, the loca-
tion of the maximum diameter aneurysm was not significantly associ-
ated with survival [HR for descending relative to arch/ascending: 1.33
(0.92–1.93), P = 0.128], although size and growth were greater for
aneurysms in the DTA. These results from ETTAA suggest that the
threshold aneurysm size for repair could be revised for stable
patients of average age. For older patients, women, and those with
higher NYHA class, ETTAA data are largely consistent with guide-
lines in the short term. These factors, together with the need for con-
comitant procedures and risk of surgery, can inform personalized
management strategies.
Aneurysm growth within a person was also a significant (perhaps
stronger) predictor of death. Thus, both current aneurysms with
diameters >6 cm, and aneurysms growing at a rate such that they will
exceed 6 cm soon should be weighed up against operative risks when
deciding on the nature and timing of intervention. Risk of death
doubled per 1 cm increase in aneurysms size, and this can be used to
predict when aneurysm risk exceeds operative risk for an individual.
This is not stated as an indication for repair in current international
guidelines but should be considered.7,19
Patients presented with widely varying aneurysm sizes, some of
which were attributed to patient age, size, smoking history, comor-
bidities, and location of the aneurysm. Faster growth in the DTA may
be related to differences in pathology in different sections of the
aorta. The more linear anatomy of this segment may also allow
greater expansion before the patient presents clinically. It may equally
be because growth of arch aneurysms was modified by previous re-
pair in adjacent segments (from type A dissection). This raises the
question of whether aneurysms in the arch and DTA require differ-
ent scanning protocols and surveillance intervals. Further investiga-
tion of these issues should be undertaken.
Health-related quality of life
At baseline, ITT and CM patients had mean (SD) HRQoL of 0.73
(0.24) and 0.68 (0.25), respectively, which is somewhat lower than
the population average in the UK (0.785 for people aged 65–74 and
0.734 for people aged >_75 years), although individuals varied wide-
ly.20 Importantly, HRQoL remained relatively stable over time for
non-smokers and therefore one might consider surveillance appro-
priate for this cohort. Comorbidities such as COPD, coronary heart
disease, and heart valve disease might be expected to reduce
HRQoL, but were not included in the multivariable model. These
comorbidities are correlated with age and frailty (indicated by use of
formal/informal care), which may have acted as surrogates since they
reflect a wider perspective on quality of life. Current smoking had the
greatest effect on HRQoL over time. In order to improve the
HRQoL of patients undergoing surveillance, smoking cessation may
be important.21
Limitations
In this observational study, data reflected routine clinical practice and
causal relationships between aneurysm diameter, growth, patient
clinical history, HRQoL, and survival cannot be concluded. No at-
tempt was made to alter routine practice so that management varied
and the population was heterogeneous. The relatively short follow-
up in ETTAA and the 1-year interval between CT scans meant that
only linear growth was apparent but we cannot exclude acceleration
in growth, particularly if it occurs between scans and immediately be-
fore dissection or rupture. If this was the case, we might speculate
that there are triggers for these clinical events.
Although hypertension is an established risk factor for poor out-
come, we have not included it because almost all patients (88%) had
hypertension and were treated with one or more anti-hypertensive
medications, and the observational nature of the study may also re-
sult in treatment by indication bias, where higher-risk patients are
treated with more powerful drugs. Such bias is impossible to adjust
for without detailed information on rationale for single/combination
drug management.
Results were not sensitive to missing data, provided that the as-
sumption of MAR holds. If there are unknown missing data mecha-
nisms, some bias in results could obtain. We consider this unlikely
given the comprehensive covariate adjustment in the imputation
process.
Strengths
A major strength of ETTAA is the large prospectively collected sam-
ple, with data provided by 30 specialist centres across England, which
ensures results are generalizable to similar populations with access to
specialist multi-disciplinary teams. Despite the observational study
design, we used rigorous scientific methods for data collection and
analysis, including core labs to minimize observer bias. We jointly
analysed aneurysm growth and survival in a single model, providing
new insight into the relative importance of initial size and rate of
growth.
Further research
There was substantial variation in maximum aneurysm size and
growth, not explained by recorded variables. Further studies should
explore genetic, physiological, and lifestyle factors that explain this
variation. Longer follow-up may help to clarify determinants of
growth. Differences in outcomes between men and women should
be investigated to eradicate possible inequalities in the care system.
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..Similarly, the (largely clinical) covariates in this study did not com-
pletely explain variation in HRQoL, which results from a range of
patient-specific concerns around health and well-being. Better under-
standing of these concerns may help patients decide whether inter-
vention will have worthwhile impact on their HRQoL.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Appendices
Appendix 1: Treatment of missing covariates
Missing values for variables included in multiple imputation are tabulated by treatment group below.
Frequencies of missing covariates at baseline by planned management group




CM (n 5 112) ITT (n 5 774)
Age, n 0 0
Sex, n 0 0
Height, n (%) 9 (8.0) 26 (3.4)
Weight, n (%) 8 (7.1) 30 (3.9)
BMI, n (%) 9 (8.0) 33 (4.3)
Care, n (%) 1 (0.9) 6 (0.8)
Smoker, n (%) 1 (0.9) 6 (0.8)
Connective tissue disorder 0 0
Extracardiac arteriopathy, n (%) 0 0
Valvular heart disease, n (%) 2 (1.8) 13 (1.7)
Coronary artery disease, n (%) 2 (1.8) 15 (1.9)
LV function, n (%) 0 10 (1.3)
LV function not measured, n (%) 55 (49.1) 347 (44.8)
Diabetes, n (%) 0 3 (0.4)
Hypertension, n (%) 0 2 (0.3)
Continued
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Little’s test for continuous covariates (age, height, weight, BMI, maximum aneurysm diameter) found weak evidence that they were not
Missing Completely At Random (P = 0.027).22 For other variables, there was evidence that survival was significantly related to missing covari-
ate status for weight, BMI, use of formal/informal care, hypertension, and extracardiac arteriopathy. NYHA missingness was significantly
associated with treatment group. These exploratory analyses suggested that imputation models could be informed by related measured
covariates in the dataset.
Development of imputation model
For survival, treatment group, pre-procedure survival time from consent, whether aneurysm was related to death or not, death status before
the index procedure, and all pre-procedure variables were included in the imputation models. Within the Multivariate Imputation by
Chained Equations procedure,23 we used predictive mean matching for all covariates included in imputation models except BMI. For imput-
ation of missing BMI, a fixed formula was used. We therefore set the number of imputations to 12. During the imputation process, we ran
10 imputation iterations for each imputed variable. The imputed values in the last iteration were used for generating an imputation dataset.
Those imputed values generated during the process were used for checking whether the values converged or not by inspecting the
trajectories.





CM (n 5 112) ITT (n 5 774)
COPD, n (%) 0 5 (0.6)
NYHA, n (%) 2 (1.8) 34 (4.4)
Beta blockers, n (%) 0 0
ACE inhibitors, n (%) 0 0
Angiotensin receptor blockers, n (%) 0 0
Calcium channel blocker use, n (%) 0 0
Other anti-hypertensives, n (%) 0 0
Any anti-hypertensives, n (%) 0 0
Statins, n (%) 0 2 (0.3)
Serum creatinine, n (%) 60 (53.6) 399 (51.6)
Haemoglobin, n (%) 64 (57.1) 420 (54.3)
Maximum aneurysm location, n (%) 0 0
Maximum aneurysm size, n (%) 0 0
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Appendix 2: Univariable Cox regression results for all cause and aneurysm-related
deaths, complete case analysis
Appendix 3: Pre-intervention longitudinal model for relation between maximum
aneurysm diameter over time and covariates
.................................................... ............................................................
....................................................................................................................................................................................................................
All-cause deaths Aneurysm-related deaths
Variable HR (95% CI) Z-test HR (95% CI) Z-test
ITT 0.35 (0.23–0.47) P < 0.001 0.28 (0.17–0.47) P < 0.001
Female sex 1.93 (1.36–2.72) P < 0.001 2.61 (1.59–4.29) P < 0.001
Use of formal/informal care 2.15 (1.40–3.29) P < 0.001 1.92 (1.02–3.61) P = 0.042
Previous cardiac interventions CABG/PCI 2.17 (1.43–3.29) P < 0.001 1.28 (0.63–2.59) P = 0.492
COPD 2.28 (1.56–3.34) P < 0.001 2.14 (1.24–3.69) P = 0.007
NYHA per class 1.47 (1.21–1.79) P < 0.001 1.35 (1.02–1.79) P = 0.037
Maximum aneurysm size per cm 1.94 (1.71–2.21) P < 0.001 2.16 (1.81–2.59) P < 0.001
Age at consent (per decade) 2.02 (1.62–2.51) P < 0.001 1.73 (1.29–2.32) P < 0.001
Height per 10 cm 0.66 (0.56–0.77) P < 0.001 0.60 (0.48–0.76) P < 0.001
Weight per kg 0.97 (0.96–0.98) P < 0.001 0.96 (0.94–0.98) P < 0.001
BMI per kg/m2 0.95 (0.91–0.99) P = 0.008 0.91 (0.86–0.97) P = 0.002
....................................................................................................................................................................................................................
Parameter fixed effects Coefficient (SE) 95% confidence interval P-Value (Z-test)
Main effects
Intercept (descending/thoracic abdominal) 5.57 (0.05) (5.48–5.67) <0.001
Arch/ascending aneurysms –0.10 (0.10) (–0.30 to 0.09) 0.296
Time per year for lower section 0.20 (0.02) (0.17–0.24) <0.001
Age at scan per decade (centred about mean age of 70.9) 0.18 (0.04) (0.11–0.25) <0.001
Connective tissue disorder 0.39 (0.17) (0.06–0.72) 0.019
Chronic obstructive pulmonary disease 0.21 (0.10) (0.02–0.40) 0.032
MRI relative to CT –0.01 (0.04) (–0.09 to 0.07) 0.807
Interactions
Additional time effect per year for MRI –0.14 (0.3) (–0.21 to –0.08) <0.001
Additional time effect per year for arch/ascending aneurysms –0.21 (0.04) (–0.29 to –0.13) <0.001
Random effects
Standard deviation(intercept) 1.06
Standard deviation (slope) 0.17
Correlation (intercept-slope) 0.40
Residual standard deviation 0.38
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Appendix 4: Joint model for longitudinal measurements of aneurysm diameter and
overall survival
Appendix 5: Final models estimates for relation between HRQoL over time and
baseline covariates
....................................................................................................................................................................................................................
Coefficient 95% confidence interval P-Valuea
Maximum aneurysm diameter (cm)
Intercept (descending/thoraco-abdominal) 6.27 (6.05 to 6.48) <0.001
Arch/ascending aneurysms –0.18 (–0.38 to 0.02) 0.085
Intention to treat (relative to CM) –0.70 (–0.93 to –0.48) <0.001
Time (per year) 0.08 (0.04 to 0.11) <0.001
Overall survival Hazard ratio 95% confidence interval P-Valuea
Current diameter (per cm) 2.02 (1.70 to 2.41) <0.001
Arch/ascending aneurysms 0.74 (0.42 to 1.28) 0.283
Intention to treat (relative to CM) 0.87 (0.57 to 1.32) 0.506
Female (relative to male) 1.84 (1.27 to 2.65) 0.001
Age at consent (per decade) 1.84 (1.44 to 2.35) <0.001
NYHA (per class) 1.23 (0.99 to 1.53) 0.060
Random effects Estimate 95% confidence interval
Standard deviation (intercept) 1.02 (0.96 to 1.08)
Standard deviation (time) 0.09 (0.05 to 0.19)
Correlation (intercept, time) 0.61 (–0.36 to 0.95)
aFrom Wald test.
....................................................................................................................................................................................................................
Parameter fixed effects Coefficient (SE) 95% confidence interval P-Value (Z-test)
Main effects
Intercept 0.838 (0.013) (0.812–0.863) <0.001
Time per year –0.010 (0.006) (–0.022 to 0.002) 0.132
(non smoker and average age)
Age per decade 0.010 (0.006) (–0.003 to 0.022) 0.122
(centred about mean of 70.9 years)
Formal/informal care –0.179 (0.020) (–0.219 to –0.140) <0.001
NYHA per class above I –0.102 (0.008) (–0.118 to -0.086) <0.001
Smoking history 0.057
Current smoker –0.049 (0.022) (–0.093 to –0.005)
Ex-smoker 0.003 (0.015) (–0.027 to 0.032)
Interactions
Additional change over time per decade increase in age –0.013 (0.003) (–0.019 to –0.007) <0.001
Additional change by smoking history 0.004
Current smoker –0.034 (0.012) (–0.058 to –0.010)
Ex smoker 0.003 (0.008) (–0.012 to 0.018)
Random effects
Standard deviation (intercept) 0.166
Standard deviation (slope) 0.040
Correlation (intercept-slope) –0.070
Residual standard deviation 0.124
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Appendix 6: Joint model for longitudinal measurements of HRQoL (EQ5D-5L) and
overall survival
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Coefficient 95% confidence interval P-Valuea
HRQoL measured by EQ5D-5L index utility
Intercept 0.727 (0.712–0.743) <0.001
Time (per year) –0.011 (–0.019 to –0.003) 0.008
Overall survival Hazard ratio 95% confidence interval P-Valuea
Current HRQoL 0.35 (0.13–0.92) 0.034
Maximum aneurysm diameter (per cm) 1.76 (1.51–2.08) <0.001
Female (relative to male) 1.61 (1.12–2.32) 0.010
Age at consent (per decade) 1.64 (1.30–2.07) <0.001
NYHA (per class) 1.10 (0.87–1.39) 0.437
Random effects Estimate 95% confidence interval
Standard deviation (intercept) 0.205 (0.193–0.217)
Standard deviation (time) 0.047 (0.037–0.060)
Correlation (intercept, time) –0.064 (–0.255 to 0.132)
aFrom Wald test.
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